# Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

> **NCT02795676** · PHASE3 · COMPLETED · sponsor: **Protalix** · enrollment: 78 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** PRX-102 (pegunigalsidase alfa)
- **BIOLOGICAL:** agalsidase beta

## Key facts

- **NCT ID:** NCT02795676
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2021-10
- **Final completion:** 2022-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795676, "Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02795676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*